CataloniaBio & HealthTech presented the 2020 Biosuccess Award to Kymos for its consolidation, international expansion and key role in dynamising the healthcare and life sciences sector in Catalonia as a science services company.
The awards ceremony took place yesterday during the CataloniaBio & HealthTech Gala, which this year was streamed online from the Gaudi’s Crypt in Colonia Güell and held during the day due to the Covid-19 situation. The sector’s main yearly event featured Secretary of Economy of the Government of Catalonia Natàlia Mas, Director General for Research and Innovation in Health Robert Fabregat, and the CataloniaBio & HealthTech board of directors. The event was followed live by 180 entrepreneurs, executives and investors.
Kymos is a contract research organisation (CRO) that has grown along with the Catalan healthcare and life sciences ecosystem. The company was founded in Barcelona in 2001 by a group of scientists with experience at pharmaceutical companies. In 2012, Kymos kicked off a strategic plan that has positioned the company, locally and internationally, as one of the benchmark CROs for the pharmaceutical, biotechnology and veterinary industries, providing support in R&D services and quality control that is essential to bringing new drugs and advanced therapies to market. Kymos currently has 150 employees at its headquarters at Parc Tecnològic de Vallès and subsidiaries in Italy and Germany and expects to see €13 million in revenue.
Natàlia Mas and the first vice-president of CataloniaBio & HealthTech Jaume Amat presented the award. "The Biosuccess Award has a double value: public recognition of a job well done and dissemination of those who are relevant to the sector. With this double look we congratulate Kymos for its trajectory and we thank its leadership among CRO's of our country" explained Amat.
Co-founder and CEO of Kymos Joan Puig de Dou, said the CataloniaBio & HealthTech Biosuccess Award “recognises how far we’ve come and our ongoing commitment to innovation and internationalisation, which has led us to have subsidiaries in Italy and Germany and clients all over the world. It also recognises the work of all CROs, which make up a significant part of the country’s healthcare ecosystem both in terms of quantity and quality.”
In her speech, CataloniaBio & HealthTech President Judit Anido highlighted the importance of this sort of company: “We need more success stories like Kymos. As we discussed just a few days ago at the presentation of the 2020 BioRegion of Catalonia Report compiled in conjunction with Biocat, one of the greatest challenges we are facing as a sector, in order to become more competitive and attract more international investment, is to consolidate our business sphere, because it is rich and innovative but still only has a few medium and large companies 'made in Catalonia'. So, CataloniaBio & HealthTech and Biocat aim to boost strategic alliances and the capacity of mature local companies like Kymos to act as a driving force over the next three years.
Previous editions of the award have gone to Oryzon (2015), Minoryx Therapeutics and Palobiofarma (2016), STAT-Dx and Mosaic Biomedicals (2017), Anaconda Biomed and Mind the Byte (2018) and Ysios Capital and Antonio Parente (2019).
The 2020 CataloniaBio & HealthTech Gala was made possible thanks to collaboration from Asabys Partners and Genesis Biomed and the support of ACCIÓ.
Related information:
Not a member of CataloniaBio & HealthTech yet?
Contact us and we will explain what we do for start-ups, companies and knowledge stakeholders in the Catalan health and life sciences ecosystem.
Comments